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Epithelial-to-mesenchymal transition (EMT) and its reverse mesenchymal-
to-epithelial transition (MET) have been suggested to play crucial roles in
metastatic dissemination of carcinomas. These phenotypic transitions
between states are not binary. Instead, carcinoma cells often exhibit a spec-
trum of epithelial/mesenchymal phenotype(s). While epithelial/mesenchy-
mal plasticity has been observed preclinically and clinically, whether any of
these phenotypic transitions are indispensable for metastatic outgrowth
remains an unanswered question. Here, we focus on epithelial/mesenchymal
plasticity in metastatic dissemination and propose alternative mechanisms
for successful dissemination and metastases beyond the traditional EMT/
MET view. We highlight multiple hypotheses that can help reconcile con-
flicting observations, and outline the next set of key questions that can
offer valuable insights into mechanisms of metastasis in multiple tumor
models.
1. Introduction
Epithelial-to-mesenchymal transition (EMT) is a cellu-
lar process loosely defined as a loss of the epithelial
traits of tight cell–cell adhesion and apico-basal polar-
ization and a gain of mesenchymal traits of motility
and invasion (Savagner, 2015). The concept of EMT
evolved from initial observations that embryonic and
adult epithelial cells converted to migratory and inva-
sive fibroblast-like cells when embedded in 3D collagen
gels (Greenburg and Hay, 1982). Defined then as a
‘transformation’, EMT has since been well studied in
gastrulation, neural crest migration, heart develop-
ment, branching morphogenesis, wound healing, fibro-
sis, and cancer metastasis. ‘Transformation’ has given
way to ‘transition’ and more recently ‘plasticity’ to
accurately represent its reversibility as well as its non-
binary nature (Jolly et al., 2015a; Nieto et al., 2016).
In the context of cancer, the hypothesis that EMT and
mesenchymal-to-epithelial transition (MET) drive the
invasion–metastasis cascade (Thiery, 2002) has been
pursued enthusiastically for over a decade (Hartwell
et al., 2006; Jung et al., 2008; Mani et al., 2007; Oca~na
et al., 2012; Onder et al., 2008; Spaderna et al., 2008;
Stankic et al., 2013; Tsai et al., 2012; Yang et al.,
2004), but recent studies have questioned the indis-
pensability of these transitions in establishing metasta-
sis (Fischer et al., 2015; Shamir et al., 2014; Somarelli
et al., 2016a; Zheng et al., 2015). These results have
stimulated provocative discussions on what steps are
necessary and sufficient to establish macrometastases
in vivo. Here, we attempt to reconcile some apparent
contradictions, and highlight key unanswered ques-
tions that need to be addressed for a better under-
standing of the contribution of EMT and MET in
metastasis in multiple tumor types.
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2. EMT and MET are not binary
processes
A tacit assumption in the proposed role of EMT and
MET during the metastasis–invasion cascade was that,
similar to the distinct developmental lineages – epithe-
lium and mesenchyme – carcinoma cells can attain
either a fully epithelial or a fully mesenchymal state
(Thiery, 2002). This assumption was supported by the
labeling of phenotypes co-expressing canonical epithe-
lial and mesenchymal markers as ‘metastable’, strongly
suggesting that these observations were a snapshot
en route to full EMT/MET and thus could not reflect
a stable state or an end point of a transition in itself
(Lee et al., 2006). Only recently has the concept of
a hybrid epithelial/mesenchymal (E/M) state been
revisited in cancer (Bronsert et al., 2014; Chao et al.,
2012; Grosse-Wilde et al., 2015; Huang et al., 2013;
Lecharpentier et al., 2011; McCart Reed et al., 2016;
Naber et al., 2013; Sampson et al., 2014; Schliekelman
et al., 2015; Strauss et al., 2011), and shown to be
stable over multiple passages in vitro (Jolly et al.,
2016). This revised understanding of cancer cell plas-
ticity has been at least in part driven by computational
modeling efforts of EMT/MET regulatory networks
(Jia et al., 2015; Li et al., 2016; Lu et al., 2013; Zadran
et al., 2014) that have triggered investigations of sin-
gle-cell phenotypes in terms of their EMT status
(Andriani et al., 2016; Grosse-Wilde et al., 2015).
In the context of wound healing and embryonic devel-
opment, the intermediate state(s) of EMT has (have)
been well studied (Arnoux et al., 2008; Futterman et al.,
2011; Johnen et al., 2012; Kuriyama et al., 2014; Leroy
and Mostov, 2007; Micalizzi et al., 2010; Revenu and
Gilmour, 2009; Shaw and Martin, 2016; Somarelli et al.,
2013). The idea that EMT need not be an ‘all-or-none’
process (Nieto, 2013) has motivated a detailed dissection
of different axes that cumulatively define EMT – base-
ment membrane remodeling, motility, cell–cell adhesion,
apical constriction, and loss of apico-basal polarity – in
sea urchin embryo. Each of these axes is regulated by a
distinct set of transcription factors, and the subcircuits
corresponding to each axes are interconnected and over-
lapping. Intriguingly, no single EMT-inducing tran-
scription factor (EMT-TF) is involved in all of these
subcircuits, highlighting the complexity of cellular plas-
ticity even in relatively simpler organisms such as sea
urchin (Saunders and McClay, 2014). These axes are
likely to influence one another, but for the sake of a bet-
ter comprehension, even if we imagine these axes to be
independent, EMT is at least a process happening in a
five-dimensional space (Fig. 1A). Induction of different
EMT-TFs may affect these five subcircuits or axes dif-
ferently, and thus, there may be varying degrees of over-
lap in the gene expression profiles obtained after
overexpression of EMT-TFs. For example, as shown in
Fig. 1B, EMT-TF1 and EMT-TF2 have both overlap-
ping and distinct influences in gene expression land-
scape, but EMT-TF3 has no overlap with gene
expression changes driven by EMT-TF1 and EMT-TF2.
Thus, EMT progression is not a unidimensional lin-
ear process, but a navigation through a rugged highly
A B
Fig. 1. Representing EMT as a multidimensional nonlinear process. (A) EMT phenotypic landscape may contain multiple axes (x1–x5). (B)
Induction of EMT by different EMT-TFs may drive epithelial cells into different regions on this multidimensional landscape (shown by
different colored dots). There may be some overlap in the effect of more than one EMT-TFs in regulation of one or more of these axes
contributing to EMT, as can be realized by projecting this multidimensional space into two principal component axes (PCA).
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nonlinear landscape (Fig. 1A,B). Also, although
assumed here as independent axes, these five aspects of
EMT may affect one another too, thus compounding
the nonlinearity of the process. Another aspect of
complexity underlying EMT may well result from
heterogeneity in cancer subtypes; for instance, the
landscape underlying this five-dimensional space may
be different for luminal vs. basal connections. Thus, it
may be extremely tricky to define EMT, but for practi-
cal purposes, we will consider here single-cell migra-
tion and/or invasion with the loss of cell–cell adhesion
as EMT, as was postulated initially (reviewed in
Cheung and Ewald, 2014). This loss of cell–cell adhe-
sion typically co-occurs with a decrease in other
epithelial traits such as loss of apico-basal polarity,
and a concomitant increase in genes often expressed
specifically in mesenchymal cells and tissues (Kalluri
and Weinberg, 2009).
Moreover, the epigenetic reprogramming accompa-
nying many of these key developmental events may
rewire EMT regulatory networks differently in differ-
ent tissue types, further amplifying the heterogeneity
and context dependence of EMT states. For instance,
in breast cancer, basal cells exhibit bivalent chromatin
states, with both activating and repressive marks for a
key EMT-TF, ZEB1, but luminal cells only have
repressive marks for ZEB1 (Chaffer et al., 2013). Thus,
basal cells are already poised to display stronger EMT
traits upon exposure to EMT-inducing cytokines such
as TGF-b, as compared to luminal cells. Similarly,
GRHL2 – a transcription factor that can inhibit EMT
(Varma et al., 2012; Walentin et al., 2015) – can be
methylated in sarcomas as compared to carcinoma
(Somarelli et al., 2016b), thus rewiring the circuit regu-
lating EMT in sarcomas.
Therefore, with such ubiquitous tissue- or even sub-
type-specific complexity and heterogeneity being
revealed, binning carcinoma phenotypes into either
fully epithelial or fully mesenchymal, and dismissing
all hybrid phenotypes as ‘metastable’, can only hamper
a better understanding of both the nuances of EMT
and MET, and how these processes may impinge on
metastasis.
3. Role of EMT-TFs in metastasis:
necessary or permissive?
In the context of cancer, Snail (SNAI1) was identified
as the first EMT-TF that directly repressed transcrip-
tion of the epithelial cell–cell adhesion molecule,
E-cadherin. Overexpression of SNAI1 in MDCK and
many carcinoma cell lines led to the loss of cell–cell
adhesion mediated by E-cadherin, transformed the
morphology of cells from epithelial to spindle-like mes-
enchymal, and enhanced their migratory and invasive
traits in vitro (Batlle et al., 2000; Cano et al., 2000).
Further work revealed a similar, but less potent role of
another EMT-TF Slug (SNAI2, a member of the Snail
family) both in vitro and in vivo (Bolos et al., 2003;
Hajra et al., 2002). SNAI1 was also shown to induce
the expression of mesenchymal markers fibronectin
and Zeb1 (Guaita et al., 2002), the latter of which is
an EMT-TF that can promote tumor invasiveness
in vitro and is correlated with tumor cell differentiation
in vivo (Aigner et al., 2007; Spaderna et al., 2008).
Later, Twist was identified as yet another EMT-TF
that inhibited E-cadherin as well as regulated other
components of EMT in MDCK cells, mammary
epithelial cells (Yang et al., 2004), and breast cancer
cell lines (Vesuna et al., 2008). Silencing Twist in 4T1
cells suppressed the number of lung metastases signifi-
cantly, however, did not completely inhibit them
(Yang et al., 2004), still leaving open the possibility
that Twist, and potentially other EMT-TFs, may act
more as catalysts rather than drivers of metastasis
(Fig. 2A). In other words, just as a catalyst can lower
the activation energy barrier for a chemical reaction,
these EMT-TFs may make a cell more poised or prone
to undergo EMT. These abovementioned studies con-
firmed that the EMT-TFs that governed developmen-
tal EMT also contributed to one or more aspects of
EMT in carcinomas in vitro, a claim that was substan-
tiated by in vivo negative correlation between these
EMT-TFs and E-cadherin expression. Thus, these
studies led to a conceptual framework suggesting that
aberrant activation of one or more EMT-TFs (result-
ing from many potential microenvironmental factors
such as hypoxia, secreted EMT-inducing cytokines
from the stroma, for example, TGF-b, or altered
degradation rate of EMT-TFs) was a necessary and
sufficient condition for metastasis.
The conceptual framework that EMT promotes
metastasis and invasion was recently challenged by
two lineage-tracing studies in mouse models of pancre-
atic and breast cancer. Zheng et al. (2015) genetically
knocked out either Twist or Snail in a spontaneous
pancreatic ductal adenocarcinoma (PDAC) model –
KPC model, but the incidence of metastasis was not
altered significantly. Multiple alternative interpreta-
tions have been proposed for this observation – (a)
knockdown of one EMT-TF need not be sufficient to
ablate EMT completely, and compensatory EMT-
inducing pathways may be present (Li and Kang,
2016), (b) the marker used for lineage tracing of cells
undergoing EMT in this study – a-smooth muscle
actin – is rarely induced spontaneously upon activation
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of EMT in this particular mouse model (Pattabiraman
and Weinberg, 2017). The other study (Fischer et al.,
2015) focused on spontaneous breast-to-lung metasta-
sis mouse models and used fibroblast-specific protein 1
(Fsp1) as a lineage-tracing marker of cells undergoing
an EMT. The authors found many Fsp1-negative cells
metastasizing to lung, suggesting that not even a tran-
sient activation of EMT was essential for metastasis.
Although the specificity and sensitivity of Fsp1 to
mark cells undergoing EMT and/or fibroblasts may be
called into question (De Chiara and Crean, 2016;
Pattabiraman and Weinberg, 2017), this study also
demonstrated that overexpression of miR-200 sup-
pressed multiple levels of many EMT-TFs, including
ZEB1, yet did not affect lung metastasis (Zheng et al.,
2015), thus providing a stronger argument for alterna-
tive mechanisms of dissemination.
In contrast, knockdown of Zeb1 in HCT116 and
SW480 cells has been shown to inhibit lung metastases
after intrasplenic or intravenous injection in nude mice
(Spaderna et al., 2008). Similarly, deletion of TWIST1
drastically inhibited lung metastasis of 4T1 cells
implanted in the mammary gland of recipient mice
(Yang et al., 2004), emphasizing a causal role of
EMT-TFs in metastasis. Technically speaking, these
studies were conducted with different approaches com-
pared to spontaneous metastasis genetically engineered
mouse models discussed above (Fischer et al., 2015;
Zheng et al., 2015). Another recent study performed in
the same KPC mouse model illustrates that depletion
of ZEB1, in sharp contrast to that of Snail or Twist,
suppresses stemness, colonization, invasion, and metas-
tasis (Krebs et al., 2017). However, ZEB1 depletion
fails to suppress metastasis completely, thereby falling
somewhat short of confirming ZEB1 as necessary and
sufficient for establishing metastasis, and leaving open
the possibility that other modes of migration may also
be important for metastasis, at least in this mouse
model.
Together, these data suggest that metastasis for all
carcinoma cells need not require an overt upregulation
of various EMT markers to gain migratory and inva-
sive traits. For instance, in tumor organoids, breast
cancer cells can invade the extracellular matrix (ECM)
by three modes – collective invasion, mesenchymal
invasion, and amoeboid invasion. In this model sys-
tem, only cells undergoing mesenchymal invasion uti-
lize an EMT-like program (Nguyen-Ngoc et al., 2012).
Conversely, collectively invading cells do not typically
express vimentin or Twist1 and maintain E-cadherin-
mediated contacts with follower cells. Rather than
undergoing an EMT, the cells undergoing collective
invasion appear to undergo a transition toward a more
basal-like phenotype, expressing K14 and p63 (Cheung
et al., 2013). Put together, it still remains a possibility
that the traits needed for successful metastasis can be
gained by altering cellular adhesion and invasion
through pathways that do not necessitate supraphysio-
logical or aberrant overexpression of one or more
EMT-TFs identified so far (Fig. 2B). In other words,
morphological changes associated with EMT can occur
without an overt upregulation of any mesenchymal
markers (Cheung and Ewald, 2014). Further, an overt
or a complete EMT may not be as efficient for metas-
tasis as the scenario when some molecular and/or mor-
phological epithelial traits are retained (Biddle et al.,
2011; Jolly et al., 2015a; Shamir et al., 2014).
4. Has a full EMT ever been seen
in vivo?
Recent progress in considering EMT as more of a
spectrum of phenotypes instead of a binary process
has driven an emerging notion that unlike during
A B
Fig. 2. Role of EMT-TFs. (A) EMT-TFs can act as catalysts of cellular plasticity. A catalyst reduces the activation energy (by an amount of
ΔE) required for the progression of a reaction. (B) Phase diagram showing different types of motility that can be possible at varying levels of
EMT-TFs and/or mesenchymal markers, and cellular motility. Dotted lines represent phase separations.
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development, in which terminally differentiated epithe-
lial and mesenchymal states exist, carcinoma cells
might undergo more partial transitions to an incom-
plete mesenchymal phenotype (Lambert et al., 2017;
Nieto et al., 2016). This notion is supported by obser-
vations that induction of a fully mesenchymal state
through overexpression of an EMT-TF may lead to a
loss of tumor-initiating potential and thus the ability
to colonize (Celia-Terrassa et al., 2012; Oca~na et al.,
2012; Ruscetti et al., 2015; Tsai et al., 2012). Earlier
studies based on similar overexpression of EMT-TFs
proposed an increase in tumor-initiating potential
(Mani et al., 2008). Reconciling these contradictions,
recent studies that categorized cells into E (epithelial),
M (mesenchymal), and hybrid E/M, instead of just E
and M, have proposed that tumor-initiating potential
might be maximum when cells are in a hybrid E/M
state (Grosse-Wilde et al., 2015; Jolly et al., 2014;
Ombrato and Malanchi, 2014; Ruscetti et al., 2015).
Such hybrid E/M cells co-expressing various epithelial
and mesenchymal markers have been observed in
breast, ovarian, lung, and renal cell carcinoma cell
lines (Andriani et al., 2016; Grosse-Wilde et al., 2015;
Huang et al., 2013; Sampson et al., 2014; Schliekelman
et al., 2015), in mouse models of prostate cancer and
PDAC (Rhim et al., 2013; Ruscetti et al., 2015), pri-
mary breast and ovarian cancer tissue (Strauss et al.,
2011; Yu et al., 2013), in the bloodstream of breast,
lung, and prostate cancer patients (Armstrong et al.,
2011; Lecharpentier et al., 2011; Yu et al., 2013), and
in metastatic brain tumors (Jeevan et al., 2016). More
importantly, triple-negative breast cancer patients had
a significantly higher number of such hybrid E/M cells
as compared to other subtypes, suggesting a correla-
tion between a hybrid E/M phenotype and tumor
aggressiveness (Yu et al., 2013).
Although it is likely that many carcinomas undergo
only a partial transition, some cancers reflect a more
complete phenotypic transition based on typical
morphological and molecular readouts. For example,
Beerling et al. (2016) identified a rare population of
E-cadlo cells that underwent spontaneous full EMT
without any exogenous induction of EMT-TFs, and
converted to an epithelial state upon reaching the
metastatic site. Another model system that tends to
exhibit a more complete EMT is the Dunning model
of prostate cancer that was derived in 1961 from a
spontaneous prostate adenocarcinoma in a Copen-
hagen rat (Dunning, 1963; Issacs et al., 1978). The DT
cell line established from this model expresses numer-
ous epithelial biomarkers, including E-cadherin, clau-
din 4, and pan-cytokeratin (Oltean et al., 2008),
possesses a cobblestone-like appearance (Oltean et al.,
2006; Somarelli et al., 2013, 2016a), and, when
implanted back into syngeneic rats, produces an extre-
mely slow-growing, indolent tumor (Presnell et al.,
1998). Serial passage in castrated rats of this tumor led
to a diverse family tree of increasingly aggressive
tumors and derivative cell lines (Issacs et al., 1982;
Smolev et al., 1977; Tennant et al., 2000). One of these
cell lines, derived from an anaplastic, highly aggressive
variant, led to the development of the anaplastic
tumor 3 (AT3) cell line. Compared to pre-EMT DT
cells, AT3 cells exhibit a post-EMT phenotype (Oltean
et al., 2006, 2008; Somarelli et al., 2013), with spindle-
like morphology, low cell–cell attachment, enhanced
invasion (Schaeffer et al., 2014), and metastatic capac-
ity (Oltean et al., 2006). Consistent with these observa-
tions, microarray analysis of DT and AT3 cells
revealed distinct epithelial and mesenchymal biomar-
ker expression, with robust expression of multiple
epithelial markers in the DTs and mesenchymal mark-
ers in the AT3s (Oltean et al., 2008). These analyses
suggest that in vivo serial passage under androgen-
deprived conditions induces a phenotypic transition
consistent with EMT in the AT3 line. Thus, AT3 cells
tend to reflect ‘epigenetically fixed’ EMT, reminiscent
of the ‘epigenetically fixed’ mesenchymal state
observed for human non-small-cell lung cancer H1703
or Calu6 cells upon prolonged exposure to TGF-b
(Thomson et al., 2011). Yet, unlike the findings dis-
cussed above in which a complete EMT reduces the
metastatic capacity of the cells, AT3 cells are highly
metastatic and remain in a ‘fixed’ mesenchymal state
during metastatic colonization (Somarelli et al.,
2016a).
Clinically, EMT has been suggested to play a role in
promoting the admixed phenotypes observed in the
case of carcinosarcomas – rare cancers comprised both
carcinomatous and sarcomatous elements. Interest-
ingly, cells expressing markers and/or morphological
features of an intermediate or hybrid epithelial/mes-
enchymal state have been observed (Bittermann et al.,
1990; DeLong et al., 1993; Haraguchi et al., 1999;
Paniz Mondolfi et al., 2013), suggesting that the mes-
enchymal component is derived via EMT from the car-
cinomatous component. Furthermore, genetic analyses
support a clonal origin of both epithelial and stromal
elements within these tumors (Somarelli et al., 2015).
While it remains to be conclusively tested whether car-
cinosarcomas represent tumors in which a portion of
the cells underwent EMT, the majority of data suggest
that, in most cases, the mesenchymal element is likely
derived from a carcinoma (Somarelli et al., 2015).
Similar to carcinosarcomas, in which tumors exhibit
admixture of two phenotypes, prostate tumors with
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areas of adenocarcinoma and neuroendocrine prostate
cancer (NEPC) have also been observed. Both the ade-
nocarcinomatous and NEPC phenotypes share com-
mon mutations, suggesting a common cell of origin
(Beltran et al., 2011; Hansel et al., 2011; Tan et al.,
2014). Likewise, a longitudinal analysis of patients
with adenocarcinoma that progresses to NEPC indi-
cated that NEPC results from clonal evolution of an
original adenocarcinoma through phenotypic plasticity
(Beltran et al., 2016). Further lineage-tracing studies
support this finding, with combined genetic loss of
Pten/Rb1/Trp53 inducing an NEPC-like transition by
upregulating stemness factor Sox2 and epigenetic
remodeling protein Ezh2 (Ku et al., 2017; Mu et al.,
2017). While not a classic example of EMT, NEPC-
like tumors represent similar phenotypic plasticity, and
some players implicated in EMT such as Snail have
also been reported in the context of NEPC-like tumors
and neuroendocrine differentiation (McKeithen et al.,
2011).
Taken together, although induction of at least a par-
tial EMT at the invasive edges in primary xenografts
has been observed in vivo (Bonnomet et al., 2012;
Klymkowsky and Savagner, 2009), a careful investiga-
tion of partial vs. full EMT needs to be conducted
in vivo to dissect the contributions of these phenotypic
transitions to invasion, dissemination, and metastasis.
It is also likely that each tumor’s requirements for
EMT/MET are slightly different depending on the
original cell of origin (e.g., basal vs. luminal), its
unique mutation profile (e.g., p53 loss), and its epige-
netics (e.g., bivalent vs. monovalent chromatin). A
more sophisticated understanding of the hybrid E/M
phenotype and its molecular underpinnings will surely
help to further elucidate the context-dependent
requirements for plasticity during various stages of the
metastatic cascade.
5. Cohesive cell migration and EMT:
mutually exclusive migration modes?
Many recent reports have suggested alternative mecha-
nisms for the escape of carcinoma cells, besides the
single-cell dissemination enabled by EMT. Specifically,
collectively invading cells have been shown to migrate
through the ECM with intact cell–cell junctions (Clark
and Vignjevic, 2015; Friedl et al., 2012). Collective
invasion need not always exhibit significant changes in
canonical epithelial and mesenchymal markers (Che-
ung et al., 2013; Shamir et al., 2014), but cells at the
leading edge of these cohorts may express certain
EMT traits (Westcott et al., 2015). A three-dimen-
sional reconstruction of serial section samples of many
tumors has suggested that cell clusters are the predom-
inant agents of invasion and that single-cell dissemina-
tion is extremely rare (Bronsert et al., 2014). Some of
these collectively invading cohorts – referred as ‘tumor
buds’ – displayed loss of cell polarity, reduced total
levels and membrane localization of E-cadherin, and
increased nuclear ZEB1. However, because these cells
were not spindle-shaped and maintained E-cadherin
levels at least partially, they were labeled as a hybrid
E/M phenotype, instead of a full EMT (Bronsert
et al., 2014; Grigore et al., 2016). It is expected that
collectively invading strands and tumor buds are pre-
cursors of clusters of circulating tumor cells (CTCs)
also called as tumor emboli, as observed in patients
with invasive melanoma, lung cancer, inflammatory
breast cancer, and clear cell renal cancer (Hou et al.,
2012; Jolly et al., 2015a; Kats-Ugurlu et al., 2009; Ye
et al., 2010), thereby suggesting that the clusters of
tumor cells retaining some of their epithelial traits can
complete the metastasis–invasion cascade and give rise
to polyclonal metastatic colonies (Cheung et al., 2016).
However, whether the clusters need upregulation of
any mesenchymal markers still remains to be investi-
gated extensively.
These clusters of CTCs, although much less preva-
lent than individually migrating CTCs, can act as pri-
mary ‘villains’ of metastasis by forming 50 times more
tumors as compared to individual CTCs (Aceto et al.,
2014). In addition, clusters may be more efficient in
resisting cell death during circulation and associate
with significantly worse outcome in patients (Cheung
and Ewald, 2016). Inhibiting players that mediate cell–
cell adhesion directly or indirectly in these clusters
such as plakoglobin or keratin 14 (K14) compromised
their metastatic potential (Aceto et al., 2014; Cheung
et al., 2016). These results are reminiscent of the essen-
tial role of E-cadherin in forming tumor emboli and
distant metastasis in inflammatory breast cancer
(Tomlinson et al., 2001) – a highly aggressive cancer
that predominantly metastasizes via clusters (Kleer
et al., 2001). Thus, retention of cell–cell adhesion as
an epithelial trait may actually be crucial to successful
metastasis in many aggressive cancers.
Activation of an EMT program – either fully or
partially – at the invasive edge can alter the ability of
primary tumor cells to intravasate and disseminate as
individual CTCs (Bonnomet et al., 2012; Roth et al.,
2016), and CTCs can display a dynamic spectrum of
EMT phenotypes (Yu et al., 2013). But, any causal
role of EMT-TFs, and by extension, of a partial or full
EMT in mediating CTC cluster formation still remains
to be thoroughly investigated. This issue is convoluted
by observations that CTC clusters may contain
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platelets that are known to secrete TGF-b (Aceto
et al., 2014), a potent mediator of EMT. Recently
developed technologies to isolate CTC clusters, such as
Cluster-Chip, may be critical in this endeavor
(Sarioglu et al., 2015).
6. Is MET required for metastasis?
While many studies have focused on the importance of
EMT during metastasis (Tsai and Yang, 2013), it has
also been hypothesized that cells transition back to an
epithelial state through MET to form macrometastases
(Thiery, 2002). This hypothesis is based upon the
observation that many metastases express epithelial
markers (Christiansen and Rajasekaran, 2006).
For example, Chao et al. (2010) examined E-cad-
herin expression in primary breast tumors and
matched metastases and found that 62% of cases had
increased E-cadherin at the metastatic site compared
to the primary tumor. Although metastatic tumors
commonly display an epithelial phenotype, it has also
long been known that undifferentiated/mesenchymal
metastases also occur in patients with cancer. Even in
a single patient, there is heterogeneity in the pheno-
typic status of multiple metastases (Spremulli and
Dexter, 1983). These observations lead us to inquire
about the requirement of MET for metastasis. Do
some disseminated tumor cells not require MET to
colonize secondary sites? Or do colonized tumor cells
retain a high level of phenotypic plasticity, thereby
priming them for multiple rounds of MET and EMT
subsequent to metastatic seeding?
Thomas Brabletz postulated two types of metastatic
progression – one based on phenotypic plasticity and
the other plasticity independent. Metastatic progres-
sion that is based on phenotypic plasticity would
require MET in order to colonize secondary sites. On
the other hand, tumor cells can acquire genetic alter-
ations that confer upon the cell all the necessary traits
for dissemination and metastatic seeding in one go and
do not require MET (Brabletz, 2012). In vivo experi-
mental evidence for these two models of metastatic
progression was demonstrated using lethal reporters
of MET that kill all the cells undergoing MET.
These reporters revealed the existence of both MET-
dependent and MET-independent paths to metastatic
progression – an MET-dependent path in carcinosar-
comas, whereas an MET-independent path in prostate
cancer (Somarelli et al., 2016a). It is likely that EMT-
TFs and microRNA families that maintain an epithe-
lial phenotype (Bracken et al., 2008; Burk et al., 2008;
Lu et al., 2013) regulate MET-dependent metastatic
mechanisms. Indeed, it was recently shown in a
spontaneous squamous cell carcinoma model that
Twist1 activation promoted EMT and CTCs. How-
ever, turning off Twist1 at distant sites allowed MET
and was essential for disseminated tumor cells to pro-
liferate and form macrometastases (Tsai et al., 2012),
reminiscent of observations that EMT typically arrests
the cell cycle (Vega et al., 2004).
Mechanisms underlying MET-independent metasta-
sis still remain elusive. One hypothesis is based on
recent observations that cells that fail to undergo cell
cycle arrest upon induction of EMT accumulate geno-
mic instability (Comaills et al., 2016). Therefore, the
cells metastasizing independent of MET may be
genomically unstable. This instability may serve to
enrich for the rare subset of cells that are likely to lead
to dedifferentiated and highly metastatic tumors that
are cross-resistant to next-line therapies (Creighton
et al., 2009; Sun et al., 2012). Therefore, therapies used
to treat cancer cells may also select for genetic alter-
ations that allow for both the maintenance of an EMT
and sustained uncontrolled proliferation, thus poten-
tially obviating the need for MET.
An alternative explanation of the results presented
above is that cells might undergo a partial MET,
which reporters could miss capturing, just as many
reporter systems may be less sensitive in capturing a
partial EMT (Li and Kang, 2016; Pattabiraman and
Weinberg, 2017). In partial MET, cells are likely to
retain their mesenchymal traits and gain their prolifer-
ative ability without the acquisition of any genetic
alterations. In a study comparing primary and meta-
static tissue from breast and prostate cancer, E-cad-
herin was found at the cellular membranes more often
in metastases than in primary tumors. However,
metastases also retained mesenchymal markers vimen-
tin and Fsp1 (Chao et al., 2012). This study suggests
that some metastases may maintain a high amount of
phenotypic plasticity and are primed to switch between
states as selection occurs during growth or by treat-
ment. Thus, it is not necessarily the phenotype that
favors metastasis, but the acquisition of the suite of
traits needed to metastasize.
A central question that remains unanswered is
whether partial EMT is the same as partial MET in its
phenotypic consequence. Most phenotypic studies have
been performed in carcinomas, which are derived from
epithelial cells. As discussed above, these cells likely
retain intrinsic epithelial phenotype and acquire migra-
tory and invasive traits, leading to a partial EMT that
can promote tumor dissemination (Jolly et al., 2015a).
Yet, as these cells are still epithelial in origin, they are
probably often less likely to undergo a complete epige-
netic reprogramming to acquire a phenotype similar to
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that of normal mesenchymal tissues. Thus, it is not
surprising that many carcinoma cells revert to an
epithelial-like state when arriving to an epithelial envi-
ronment to form metastases. It is crucial that these
cells are able to reactivate the cell cycle to proliferate
and colonize; if the cells become fixed in a mesenchy-
mal-like phenotype and break the connection between
the epithelial phenotype and cell cycle activation,
either by mutation or by epigenetic reprogramming,
their metastatic potential might be severely compro-
mised (Fig. 3).
Interestingly, sarcomas provide a unique perspective
on the need for MET during metastasis. Sarcomas are
cancers of a mesenchymal lineage. These cancers are
highly aggressive and metastatic, and upregulation of
mesenchymal biomarkers is observed in metastases
compared to primary tumors (Shen et al., 2011; Wiles
et al., 2013), suggesting that these tumors metastasize
via an MET-independent route. It is possible that sar-
coma cells are primed for enhanced metastatic capacity
because of their mesenchymal lineage and that the
acquisition of growth advantages during cancer initia-
tion enables these cancers to metastasize readily via an
MET-independent route. Clinically, sarcomas occur in
younger patients and have a shorter overall survival
compared to carcinomas (Siegel et al., 2017), suggest-
ing that the rate-limiting step for metastasis of these
cancers may indeed be tumor initiation. Conversely, in
carcinomas, sustained cell growth is commonly cou-
pled to MET during the formation of macrometas-
tases. In this scenario, induction of a MET might be
the rate-limiting step in metastasis.
7. Role of the microenvironment
Phenotypic plasticity can be influenced by the tumor
microenvironment; for instance, upregulation of
hypoxia (Sun et al., 2009) and soluble factors released
by macrophages and other infiltrating immune cells
(Huang and Du, 2008; Toh et al., 2011) leads to
upregulation of EMT-TFs and EMT induction. The
importance of the microenvironment in driving a
metastatic phenotype is underscored by the presence of
‘tumor microenvironment of metastasis’ (TMEM), in
which the surrounding microenvironmental niche pro-
motes metastatic dissemination and colonization. For
example, factors such as hypoxia (Ju et al., 2017),
tumor-infiltrating neutrophils (Gordon-Weeks et al.,
2017), and radiation treatment (Bouchard et al., 2017;
Ruegg et al., 2011) have been demonstrated to gener-
ate a metastasis-promoting microenvironment. Not
only do these microenvironmental factors play impor-
tant roles in creating a prometastasis environment, but
also the spatial relationships among these factors are
critical. Along these lines, spatial proximity of an
endothelial cell, a perivascular macrophage, and an
invasive cancer cell overexpressing Mena (a key actin
polymerization regulatory protein) – as identified by
intravital imaging – was highly correlated with metas-
tasis (Robinson et al., 2009). Based on these insights,
it has been suggested that normalizing the tumor
microenvironment could be a potential therapeutic
strategy to improve patient outcomes (Jain, 2013).
Dynamics of the microenvironment can enable a
passive shedding of cancer cells into circulation. This
Fig. 3. Plasticity-dependent and plasticity-independent pathways to metastasis. (A) In MET-dependent metastasis, post-EMT-like cancer
cells upregulate invasive programs that facilitate dissemination and seeding (red curve). The invasive program comes at a cost; EMT
induction leads to downregulation of proliferative potential (blue curve). Re-establishment of an epithelial-like phenotype via MET at the
metastatic site awakens the proliferative potential necessary for the formation of macrometastases. (B) In MET-independent metastasis,
therapy, epigenetic reprogramming, acquisition of novel mutations, or other mechanisms induce a post-EMT state that becomes fixed in a
proliferationhigh/invasionhigh phenotype. Cells metastasizing via an MET-independent pathway may be more aggressive, stem-like,
chemorefractory, and more likely to seed and re-seed further metastases.
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mode would be instead of a postulated active crawling
or migration of cancer cells into the circulation or
toward any nutrient or chemokine gradient and cleav-
age of ECM by secreting proteases (Bockhorn et al.,
2007) For instance, blood vessels have been proposed
to engulf clusters of cancer cells, thus obviating the
need for EMT (Fang et al., 2015). These clusters may
avoid cell death in circulation by cell–cell contact-
mediated survival signals (Shen and Kramer, 2004)
and may already be enriched for players such as Jag1
(Cheung et al., 2016) that can help them evade multi-
ple therapies (Boareto et al., 2016; Li et al., 2014; Shen
et al., 2015; Sim~oes et al., 2015) and colonize success-
fully (Sethi et al., 2011). Not surprisingly, Jag1 is
enriched in aggressive cancers such as basal-like breast
cancer (BLBC) (Reedijk et al., 2008) and can con-
tribute to the abnormal vasculature typically observed
in cancers (Benedito et al., 2009; Boareto et al.,
2015a). Moreover, Fringe, a glycosyltransferase that
inhibits the binding of Notch to Jag1 (Boareto et al.,
2015b; Jolly et al., 2015b), is lost in BLBC (Zhang
et al., 2014).
Therefore, active crawling or migration of cells dri-
ven by a partial or full EMT, often activated by over-
expression of EMT-TFs, is not certainly the only route
to metastasis. It is not inconceivable that tumor cell
dissemination – particularly cluster-based dissemina-
tion – is a passive process where cells that can navigate
the fitness bottlenecks from an evolutionary standpoint
eventually form metastases (Amend et al., 2016). Both
genetic and nongenetic heterogeneity may be crucial or
even synergistic in conferring a rare subpopulation of
cells with high adaptability or plasticity that lets them
transit the entire invasion–metastasis cascade. Such
plasticity may coincide with co-expression of many
epithelial and mesenchymal markers, owing to pheno-
typic alterations that accumulate over multiple steps of
the entire metastatic cascade.
8. Conclusion
Single-cell dissemination as enabled by EMT followed
by a MET has been considered to be a hallmark of
metastasis. However, alternative modes of dissemina-
tion, such as collective or cluster-based migration and
invasion, can exist where cells need not shed cell–cell
adhesion completely, and may not even exhibit an
overt upregulation of mesenchymal markers, while
having gained the traits of migration and invasion.
Furthermore, disseminated cancer cells may undergo
metastatic colonization via an MET-independent path-
way. Together, the wealth of data acquired thus far
support a more nuanced view of the role of EMT/
MET in cancer metastasis. While in some cases, EMT/
MET are critically important, in other scenarios EMT
and MET may not be playing a necessary role, but
more of permissive and potentially catalytic roles by
regulating phenotypes that speed the processes neces-
sary to escape and colonize.
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